InMed reports FY2025 net loss of $8.2M; BayMedica revenue up 8% to $4.9M

InMed Pharmaceuticals Inc.

Net loss $8.2M vs $7.7M prior year; diluted EPS ($8.36) vs ($20.14) on higher share count.
Cash $11.1M, up from $6.6M; expected to fund operations into Q4 2026.
BayMedica segment sales $4.9M (+8% YoY); gross profit rose to $1.7M from $1.1M.
INM-901 Alzheimer's candidate: significant neuroinflammation reductions and oral bioavailability data.
INM-089 dry AMD program selected intravitreal formulation; doses up to 10x safety margin.

item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.